NHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia.
ICO Centre René Gauducheau, Saint Herblain, France.
Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.
Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).
mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28. χ tests for trend were used to examine the relationship between HRQL, PS and mGPS. Cox proportional hazards regression was used to assess associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS).
Inflammatory markers were available in 516 of 948 patients in GCIG SBS. 200(39%) had potentially platinum sensitive ROC with ≥3 lines of chemotherapy, 316(61%) had platinum resistant ROC. 282(55%), 123(24%), 111(22%) had mGPS of 0, 1, 2, respectively. Median OS (months) was 18.1, 9.6, and 6.6 for mGPS 0, 1, and 2 respectively. mGPS was an independent predictor of OS after adjusting for PS and platinum sensitivity (p<0.001). mGPS remained a predictor of OS after adjusting for physical function, role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors (p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001). Higher mGPS was associated with worse HRQL, independent of PS.
The mGPS is an independent predictor of OS in ROC after adjusting for HRQL and clinicopathological factors. Higher mGPS is associated with worse HRQL independent of PS. mGPS is simple, inexpensive and may be suitable for clinical practice, clinical trial patient selection and stratification.
改良格拉斯哥预后评分（mGPS）可预测多种晚期癌症的生存率，但尚未在复发性卵巢癌（ROC）中进行评估。本研究旨在确定 mGPS 在 ROC 中的有效性，探讨其与健康相关生活质量（HRQL）和 ECOG 表现状态（PS）的相关性。
mGPS 基于血清 C 反应蛋白（CRP）和白蛋白，评分范围为 0（最低）至 2（最高）。HRQL 采用 EORTC QLQ C-30 和 OV-28 进行测量。采用 χ 趋势检验分析 HRQL、PS 和 mGPS 之间的关系。采用 Cox 比例风险回归评估 mGPS、HRQL、临床病理因素与总生存（OS）之间的关系。
GCIG SBS 中 948 例患者中有 516 例有炎症标志物数据。200 例（39%）为潜在铂类敏感的 ROC，化疗≥3 线，316 例（61%）为铂类耐药的 ROC。mGPS 分别为 0、1、2 的患者分别为 282 例（55%）、123 例（24%）、111 例（22%）。mGPS 为 0、1、2 的患者中位 OS（月）分别为 18.1、9.6 和 6.6。调整 PS 和铂类敏感性后，mGPS 是 OS 的独立预测因子（p<0.001）。调整体力功能、角色功能、总体健康状况、腹部/GI 症状和多个临床病理因素后，mGPS 仍然是 OS 的预测因子（p=0.02）。较差的 PS 和较高的 mGPS 与较差的 HRQL 相关（p<0.001）。较高的 mGPS 与 PS 无关，与较差的 HRQL 相关。
调整 HRQL 和临床病理因素后，mGPS 是 ROC 中 OS 的独立预测因子。较高的 mGPS 与 PS 无关，与较差的 HRQL 相关。mGPS 简单、廉价，可能适合临床实践、临床试验患者选择和分层。
